JAGX
NASDAQ · Pharmaceuticals
Jaguar Health Inc
$0.40
0.00 (-0.69%)
Financial Highlights (FY 2026)
Revenue
5.81B
Net Income
-26,985,912,578
Gross Margin
67.2%
Profit Margin
-464.2%
Rev Growth
-1.3%
D/E Ratio
3.64
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.81B | 5.89B | 728.2K | 878.3K |
| Gross Profit | 3.91B | 3.96B | 446.4K | 538.4K |
| Operating Income | -24,093,762,537 | -21,961,096,094 | 200.8K | 257.3K |
| Net Income | -26,985,912,578 | -24,597,246,627 | 171.9K | 200.8K |
| Gross Margin | 67.2% | 67.2% | 61.3% | 61.3% |
| Operating Margin | -414.4% | -373.0% | 27.6% | 29.3% |
| Profit Margin | -464.2% | -441.0% | 23.6% | 22.9% |
| Rev Growth | -1.3% | -1.3% | -5.9% | +16.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 355.6K | 355.6K | 719.4K | 546.9K |
| Total Equity | 97.7K | 97.7K | 1.37M | 1.50M |
| D/E Ratio | 3.64 | 3.64 | 0.52 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -23,127,463,475 | -22,251,458,680 | 249.9K | 289.1K |
| Free Cash Flow | — | — | 132.1K | 184.4K |